MedTrace Logo

Pain Control for Undergoing Costal Cartilage Harvesting

NCT05285566 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2025-09-12

No results posted yet for this study

Summary

The purpose of this study is to find out whether injecting the U.S. Food and Drug Administration (FDA) approved drug EXPAREL®, a long acting (approximately 96 hours) numbing medication, will reduce pain after rib cartilage removal in comparison to the standard injection of XYLOCAINE®.

Conditions

  • Nasal Surgery

Interventions

DRUG

Exparel

106mg (8 mL) subcutaneous injection injected after costal cartilage harvest

DRUG

Xylocaine

8 mL of 1% lidocaine with 1:100,000 of epinephrine into costal cartilage wound site

Sponsors & Collaborators

Principal Investigators

  • Michael D Olson, MD · Mayo Clinic

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-05-04
Primary Completion
2026-08-31
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05285566 on ClinicalTrials.gov